Zhejiang Provincial Key Laboratory of Medical Genetics, Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, China.
NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
J Med Virol. 2023 Aug;95(8):e28998. doi: 10.1002/jmv.28998.
Over 3 years, humans have experienced multiple rounds of global transmission of SARS-CoV-2 and its variants. In addition, the widely used vaccines against SARS-CoV-2 involve multiple strategies of development and inoculation. Thus, the acquired immunity established among humans is complicated, and there is a lack of understanding within a panoramic vision. Here, we provided the special characteristics of the cellular and humoral responses in 2-year convalescents after inactivated vaccines, in parallel to vaccinated COVID-19 naïve persons and unvaccinated controls. The decreasing trends of the IgG, IgA, and NAb, but not IgM of the convalescents were reversed by the vaccination. Both cellular and humoral immunity in convalescents after vaccination were higher than the vaccinated COVID-19 naïve persons. Notably, inoculation with inactivated vaccine fueled the NAb to BA.1, BA.2, BA.4, and BA.5 in 2-year convalescents, much higher than the NAb during 6 months and 1 year after symptoms onset. And no obvious T cell escaping to the S protein was observed in 2-year convalescents after inoculation. The study provides insight into the complicated features of human acquired immunity to SARS-CoV-2 and variants in the real world, indicating that promoting vaccine inoculation is essential for achieving herd immunity against emerging variants, especially in convalescents.
在过去的三年中,人类经历了多轮 SARS-CoV-2 及其变体的全球传播。此外,广泛使用的 SARS-CoV-2 疫苗涉及多种开发和接种策略。因此,人类建立的获得性免疫较为复杂,缺乏全景式的理解。在这里,我们提供了在灭活疫苗接种 2 年后的恢复期患者的细胞和体液反应的特殊特征,同时与接种过 COVID-19 疫苗的未感染者和未接种疫苗的对照组进行了比较。恢复期患者的 IgG、IgA 和 NAb 水平呈下降趋势,但 IgM 水平没有下降,而接种疫苗则逆转了这一趋势。接种疫苗后,恢复期患者的细胞和体液免疫均高于接种过 COVID-19 疫苗的未感染者。值得注意的是,接种灭活疫苗可使 2 年恢复期患者对 BA.1、BA.2、BA.4 和 BA.5 的 NAb 水平升高,远高于症状出现后 6 个月和 1 年的 NAb 水平。接种后,在 2 年恢复期患者中未观察到针对 S 蛋白的 T 细胞逃逸。本研究深入了解了人类对 SARS-CoV-2 及其变体在现实世界中获得性免疫的复杂特征,表明促进疫苗接种对于实现针对新兴变体的群体免疫至关重要,尤其是在恢复期患者中。